Welcome!

News Feed Item

China Pharma Holdings, Inc. Reports Full Year 2013 Financial Results

HAIKOU CITY, China, March 21, 2014 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

Full Year Highlights

  • Revenue decreased 40% to $32.8 million in fiscal year 2013 from $54.5 million in fiscal year 2012.
  • Loss from operations was $18.6 million in fiscal year 2013 compared to income from operation of $5.9 million in 2012, a decrease of $24.5 million.
  • Net loss was $20.0 million in fiscal year 2013 compared to net income of $4.6 million in 2012, a decrease of $24.6 million.  Loss per common share was 46 cents per basic and diluted share in fiscal 2013 compared with earnings of 11 cents per basic and diluted share in 2012.
  • Gross loss margin was (1.5%) in fiscal year 2013, compared to gross profit margin of 26% in fiscal 2012. Without the effect of inventory obsolescence, management estimates that our gross profit would have been approximately 29% in both 2013 and 2012.

"China provides a unique opportunity to its pharmaceutical industry; however, real challenges remain: from compulsory new GMP upgrading requirement and rising pricing pressure to extended regulatory review time for new medical production applications, which temporally impacted our performance negatively in 2013," said Ms. Zhilin Li, China Pharma's Chairman and CEO. Ms Li continued, "we have maintained a conservative stance in general sales and credit policies in 2013 in order to ensure the capital requirements for new GMP upgrading requirements, and control and improve the condition of our accounts receivable. As of January 1, 2014, we have suspended our dry powder injectable and liquid injectable production lines due to the failure to meet the new GMP upgrading deadline. However, we have already completed the overall architectural structure of our new facility, and are in the process of installation and commissioning the equipment. We are looking forward to submitting the application for new GMP certificate in the second quarter of 2014."

Full Year Results

Revenues for the year ended December 31, 2013 were $32.8 million, a decrease of 40% from revenues of $54.5 million for the year ended December 31, 2012. This decrease primarily resulted from decreases in sales throughout all our product categories, especially our CNS Cerebral &Cardio Vascular products (decreased by roughly $8 million) and our Anti-Viro/Infectious & Respiratory products (decreased by roughly $6.3 million).

Gross loss for the year ended December 31, 2013 was $0.5 million, compared to gross profit of $14.1 million in 2012, a decrease of $14.6 million. Gross loss margin was (1.5%) in 2013, compared to gross profit margin of 25.8% for 2012. Without the effect of inventory obsolescence, management estimates that our gross profit would have been approximately 29% in both 2013 and 2012. The Healthcare Reform instituted by the Chinese government since 2009 contains pricing controls, which have resulted in margin compression in most pharmaceutical products on the market today, especially in the generic space where many of our products are sold. Going forward, we expect to see continued pricing pressures on most products, while new products could help to support overall gross margin once they are launched. We launched Candesartan in November 2013 and started its marketing activities.

Selling, general and administrative expenses in 2013 were $5.7 million, or 17.3% of sales, compared to $6.4 million, or 11.8% of sales, in 2012. For the year ended December 31, 2013, the Company's research and development expense was $1.7 million, compared to $0.4 million in 2012. The increase in R&D expense was mainly due to the fact that the Company has started to take a dominant position in the research activities of formulation screening, new technology exploration, technical criteria improvement in 2013. We expect this new model will improve our exploration channels for pipeline products.

For the year ended December 31, 2013, the Company's bad debt expense was $10.8 million, compared to a bad debt expense of $0.9 million in 2012. In the fourth quarter of 2013, we implemented a one-time trade receivables collection discount program to accelerate the collection of old accounts receivable. Management negotiated settlement offers with certain customers from which we had accounts receivable balances of approximately $8.0 million that were greater than one year past due. The offers to these customers were comprised of discounts ranging from 15% to 30% of the total past due balance in exchange for payment of the remaining balance in full by December 31, 2013. As a result of this program, we were able to collect cash of approximately $5.85 million after granting those customers discounts totaling $2.1 million. The collection discounts were recorded as bad debt expense.

Operating loss was $18.6 million in 2013 compared to operating income of $5.9 million in 2012, a decrease of $24 million. The lower operating income in 2013 reflects lower revenue, higher inventory obsolescence and higher bad debt expenses in 2013.

For the years ended December 31, 2013 and 2012, our income tax rate was 15%. Income tax expense was $1.1 million and $1.0 million for the years ended December 31, 2013 and 2012, respectively. We renewed our "National High-Tech Enterprise" status ("National HT Status") from the PRC government in the third quarter of 2013. With this designation, for the years ending December 31, 2014, 2015 and 2016, we will continue to enjoy a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.

Net loss for the year 2013 was $20.0 million, or $0.46 per basic and diluted share, compared to net income of $4.6 million, or $0.11 per basic and diluted share in 2012. The decrease in net income was mainly due to the decrease in revenue, increase in inventory obsolescence, and increase in bad debt expense.

Financial Condition

As of December 31, 2013, the Company had cash and cash equivalents of $6.0 million compared to $4.0 million as of December 31, 2012. Year-over-year, working capital decreased to $72 million in 2013 from $98 million in 2012 and the current ratio was 7.0 times in 2013, decreased from 7.7 times in 2012.

Our accounts receivable balance decreased to $45.1 million at December 31, 2013 from $66.2 million at December 31, 2012. Our receivables decreased due to our enhanced collection efforts, increased allowance and the trade receivables collection discount program implemented in the fourth quarter of 2013 to encourage the collection of accounts receivable aged over one year, and a decrease in sales.

For the year ended December 31, 2013, cash flow from operating activities was $8.6 million, as compared to $3.6 million in 2012.

In addition, we entered an eight-year construction loan facility with a bank on June 21, 2013. The total loan facility amount is RMB 80,000,000 (approximately $13 million). We utilized RMB 76,283,350 (approximately $12.4 million) of the facility through March 7, 2014. The cash flow generated from operating activities and the newly executed construction loan facility is being used to fund the construction of our new GMP upgrading project.

Pipeline Update

As of December 31, 2013, China Pharma had various pipeline drugs in different stages of active development. Some of these are highlighted below:

  • Antibiotic Combination - We completed the Phase I clinical trials of our novel cephalosporin-based combination antibiotic. We are currently in Phase II of the clinical trial, due to the increasedregulatory requests for clinical works.
  • ŸRosuvastatin - Rosuvastatin is a generic form of Crestor, a drug for the treatmentof high blood cholesterol levels. Clinical trials for this generic drug were completed in the fourth quarter of 2010 and we have submitted an application for production approval, and are performing supplemental trials of related materials pursuant to the new criteria requirements.
  • Heart Disease Drug - We have an oral solution for the treatment of coronary heart diseasein our new product pipeline. This product comes with a patented Traditional Chinese Medicine (TCM) formula and is currently in Phase III clinical trials following the improved regulatory criteria for clinical works.

Conference Call

The Company will hold a conference call at 8:30 am ET on March 21, 2014 to discuss fiscal year 2013 results. Listeners may access the call by dialing 1-800-742-9301or +65-3158-0667 for international callers, Conference ID # 8557805. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com. A replay of the call will be accessible through March 28, 2014 by dialing 1-855-452-5696 or +61-281-990-299 for international callers, Conference ID # 8557805.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

Contact:

China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: [email protected]

- FINANCIAL TABLES FOLLOW - 

 

CHINA PHARMA HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS



December 31,


2013


2012

ASSETS




Current Assets:




Cash and cash equivalents

$      5,993,139


$     4,029,708

Banker's acceptances

336,003


101,570

Trade accounts receivable, less allowance for doubtful




accounts of $13,301,622 and $4,429,945, respectively

45,147,602


66,175,570

Other receivables, less allowance for doubtful




accounts of $43,064 and $49,881, respectively

175,739


80,799

Advances to suppliers

7,626,716


4,816,354

Inventory, less allowance for obsolescence 




of $8,027,126 and $1,769,984, respectively

24,677,120


36,359,516

Deferred tax assets

-


967,671

Total Current Assets

83,956,319


112,531,188





Advances for purchases of intangible assets

41,701,505


39,263,977

Property and equipment, net of accumulated depreciation of




$5,264,350 and $4,273,373, respectively

30,241,337


9,031,894

Intangible assets, net of accumulated amortization of




$3,812,992 and $2,944,726, respectively

1,711,793


2,412,854

TOTAL ASSETS

$ 157,610,954


$ 163,239,913





LIABILITIES AND STOCKHOLDERS' EQUITY




Current Liabilities:




Trade accounts payable

$    1,877,437


$     2,841,862

Accrued expenses

323,651


202,185

Accrued taxes payable

-


2,426,826

Other payables

1,312,361


1,094,886

Advances from customers

2,228,238


1,945,984

Other payables - related parties

1,354,567


1,354,567

Short-term notes payable

4,909,662


4,761,073

Total Current Liabilities

12,005,916


14,627,383

Non-current Liabilities:




Construction loan facility

12,484,183


-

Long-term deferred tax liability

176,414


95,963

Total Liabilities

24,666,513


14,723,346

Stockholders' Equity:




Preferred stock, $0.001 par value; 5,000,000 shares authorized;




no shares issued or outstanding

-


-

Common stock, $0.001 par value; 95,000,000 shares authorized;




43,579,557 shares and 43,579,557 shares outstanding, respectively   

43,580


43,580

Additional paid-in capital

23,590,204


23,590,204

Retained earnings

88,896,276


108,904,325

Accumulated other comprehensive income

20,414,381


15,978,458

Total Stockholders' Equity

132,944,441


148,516,567

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$ 157,610,954


$ 163,239,913

 

CHINA PHARMA HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME



For the Years


Ended December 31,


2013


2012

Revenue

$    32,806,678


$     54,507,049

Cost of revenue

23,405,886


38,660,814

Inventory obsolescence

9,881,711


1,769,984





Gross (loss) profit

(480,919)


14,076,251





Operating expenses:




Selling expenses

3,284,905


3,535,214

General and administrative expenses

2,404,338


2,874,644

Research and development expenses               

1,683,244


438,662

Bad debt expense

10,752,991


871,612

Impairment of intangible assets

-


593,095

Total operating expenses

18,125,478


8,313,227





Government subsidy income

-


141,987





(Loss) income from operations

(18,606,397)


5,905,011





Other income (expense):




Interest income

8,457


4,944

Interest expense

(348,696)


(308,375)

Net other expense

(340,239)


(303,431)





(Loss) income before income taxes

(18,946,636)


5,601,580

Income tax expense

(1,061,413)


(983,921)

Net (loss) income

(20,008,049)


4,617,659

Other comprehensive income - foreign 




currency translation adjustment

4,435,923


1,274,091

Comprehensive (loss) income

$    (15,572,126)


$      5,891,750

(Loss) earnings per share:




Basic

$               (0.46)


$               0.11

Diluted

$               (0.46)


$               0.11

 

CHINA PHARMA HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS



For the Years


Ended December 31,


2013


2012

Cash Flows from Operating Activities:




Net (loss) income

$ (20,008,049)


$    4,617,659

Depreciation and amortization

1,612,830


1,462,771

Stock based compensation

-


141,721

Bad debt expense

10,752,991


871,612

Deferred income taxes

1,061,413


(430,250)

Inventory obsolescence reserve

6,121,655


1,769,984

Impairment of intangible assets

-


593,095

Changes in assets and liabilities:




Trade accounts and other receivables

3,633,180


(1,098,322)

Advances to suppliers

(2,625,629)


1,014,760

Inventory

11,155,810


(4,702,575)

Trade accounts payable

(1,183,733)


(306,040)

Accrued expenses and other liabilities

356,640


246,817

Accrued taxes payable

(2,499,949)


(683,357)

Other payables

-


744

Advances from customers

218,656


145,201

Net Cash Provided by Operating Activities

8,595,815


3,643,820





Cash Flows from Investing Activities:




Advances for purchases of intangible assets

(298,631)


(3,218,035)

Advances for purchases of property and equipment

-


(1,612,670)

Purchases of property and equipment

(18,794,261)


(156,878)

Net Cash Used in Investing Activities

(19,092,892)


(4,987,583)





Cash Flows from Financing Activities:




Proceeds from construction term loan

12,322,648


-

Proceeds from issuance of notes payable

-


793,223

Proceeds from related party loan

-


493,004

Net Cash Provided by Financing Activity

12,322,648


1,286,227





Effect of Exchange Rate Changes on Cash

137,860


36,390

Net (Decrease ) Increase in Cash and Cash Equivalents

1,963,431


(21,146)

Cash and Cash Equivalents at Beginning of Period

4,029,708


4,050,854

Cash and Cash Equivalents at End of Period

$     5,993,139


$    4,029,708





Supplemental Cash Flow Information:




Cash paid for interest

$        569,855


$       298,433

Cash paid for income taxes

2,481,164


2,138,853





Supplemental Noncash Investing and Financing Activities:




Accounts payable for purchases of property and equipment

$        144,243


$       151,731

Accounts receivable collected with banker's acceptances

8,317,045


4,354,825

Purchases of property and equipment paid with banker's acceptances       

2,564,790


1,540,820

Advances for purchases of intangibles paid with banker's acceptances

897,820


27,909

Inventory purchased with banker's acceptances

4,626,165


2,768,805

SOURCE China Pharma Holdings, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software sec...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to connect your brand strategy with the right consumer. 24Notion ranked #12 on Corporate Social Responsibility - Book of List.
SYS-CON Events announced today that Roundee / LinearHub will exhibit at the WebRTC Summit at @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LinearHub provides Roundee Service, a smart platform for enterprise video conferencing with enhanced features such as automatic recording and transcription service. Slack users can integrate Roundee to their team via Slack’s App Directory, and '/roundee' command lets your video conference ...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Adobe is changing the world though digital experiences. Adobe helps customers develop and deliver high-impact experiences that differentiate brands, build loyalty, and drive revenue across every screen, including smartphones, computers, tablets and TVs. Adobe content solutions are used daily by millions of companies worldwide-from publishers and broadcasters, to enterprises, marketing agencies and household-name brands. Building on its established design leadership, Adobe enables customers not o...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera M...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...